Importantly, we showed that FTO exerts its oncogenic role in AML in an m6A-dependent manner as an m6A demethylase.55 Briefly, FTO post-transcriptionally regulates the expression of its critical target RNAs, such as ASB2 and RARA, two genes that have been implicated in leukemia cell proliferation and drug response.56–58 We performed transcriptome-wide m6A-seq, luciferase reporter and mutagenesis assays, mRNA stability assays and gene-specific m6A-qPCR assays. The gene discussed is FTO; the disease is leukemia.